Korean biotech startup VS PharmTech announced on September 18th that it has successfully raised Series B bridge funding, though the investment amount remains undisclosed. The funding round was led by Enlight Ventures and JCH Investment, specifically aimed at facilitating global technology transfer initiatives.

The company’s flagship drug candidate, VS-101, is a radiosensitizer administered orally before radiation therapy to amplify the anticancer effects of radiation treatment. The drug has shown promising results in domestic Phase 1 clinical trials, with all patients achieving complete response (CR), demonstrating both the safety profile and therapeutic potential of VS-101.

Following VS PharmTech’s participation in BIO International Convention 2025 in Boston this past June—the world’s largest biotechnology industry exhibition—the company has entered into non-disclosure agreements (NDAs) with 11 global companies to discuss potential technology transfer opportunities.

Beyond discussions with NASDAQ-listed companies, VS PharmTech is actively negotiating technology transfer and joint venture agreements with pharmaceutical companies across multiple markets, including China, Brazil, Russia, and Saudi Arabia.

The company is currently conducting Phase 2 clinical trials for head and neck cancer treatment in collaboration with Yale Cancer Center, NYU Langone Health, and Kansas Cancer Center in the United States. VS PharmTech aims to obtain interim data from the Phase 2 trials by the end of 2025, with trial completion targeted for 2026.

“This investment serves as a catalyst for our upcoming global technology transfer deals,” said Park Shin-young, CEO of VS PharmTech. “It will create concrete momentum for the technology transfer, joint development, and strategic investment discussions we have been pursuing.”

The bridge funding positions VS PharmTech to capitalize on growing international interest in its innovative radiosensitizer technology as the company advances toward potential global partnerships and market expansion.